<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090761</url>
  </required_header>
  <id_info>
    <org_study_id>SAPB in thoracoscopy</org_study_id>
    <nct_id>NCT05090761</nct_id>
  </id_info>
  <brief_title>Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy</brief_title>
  <official_title>Is Serratus Anterior Plane Block (SAPB) With Adjuvant Medications Better at Managing Post-operative Pain Than Serratus Anterior Plane Block With Bupivacaine Alone in Patients Undergoing Video-assisted Thoracoscopy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of the serratus anterior plane&#xD;
      block (SAPB) alone (30 mL of 0.25% bupivacaine) or plus Magnesium (150 mg of magnesium&#xD;
      sulfate) or plus Magnesium + Buprenorphine (300 mcg) as adjuvants can improve post-operative&#xD;
      pain in patients undergoing video-assisted thoracoscopic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many thoracic surgeons have switched from open thoracotomy to video-assisted thoracoscopy&#xD;
      (VATS), when possible, in efforts to decrease length of hospital stays, decrease analgesic&#xD;
      requirements, and decrease postoperative pain.&#xD;
&#xD;
      The serratus anterior plane block (SAPB) has been used effectively for the management of pain&#xD;
      in the context of rib fractures, rib contusions, thoracoscopic surgery, thoracotomy, breast&#xD;
      surgery, and post-mastectomy pain syndrome. It has been shown to have similar efficacy to&#xD;
      thoracic epidurals in open thoracotomy.&#xD;
&#xD;
      The serratus anterior muscle originates from the anterior aspect of ribs 1 through 7-10 and&#xD;
      inserts on the medial border of the scapula. It consists of 7 to 10 serrated tendinous&#xD;
      projections that originate on each rib and is innervated by the long thoracic nerve. Deep and&#xD;
      superficial potential spaces bound the serratus anterior. At the level of the fifth rib, the&#xD;
      superficial plane forms from the anterior aspect of the serratus anterior and the posterior&#xD;
      aspect of the latissimus dorsi muscle. The deep plane forms from the posterior aspect of the&#xD;
      serratus anterior and the external intercostal muscles and ribs. Injecting in either plane&#xD;
      will achieve analgesia to the anterolateral chest wall with reportedly similar efficacy and&#xD;
      an equivalent area of cutaneous sensory loss.&#xD;
&#xD;
      The SAPB targets the lateral cutaneous branches of the thoracic intercostal nerves, which&#xD;
      arise from the anterior rami of the thoracic spinal nerves and run in a neurovascular bundle&#xD;
      immediately inferior to each rib. At the midaxillary line, the lateral cutaneous branches of&#xD;
      the thoracic intercostal nerve traverse through the internal intercostal, external&#xD;
      intercostal, and serratus anterior muscles innervating the musculature of the lateral thorax.&#xD;
      These branches of the intercostal nerves, therefore, travel through the two potential spaces&#xD;
      described above. Local anesthetic inserted into these planes will spread throughout the&#xD;
      lateral chest wall, resulting in paresthesia of the T2 through T9 dermatomes of the&#xD;
      anterolateral thorax.&#xD;
&#xD;
      Rebound pain is possible after serratus anterior block because analgesia provided by&#xD;
      bupivacaine typically lasts around six hours. Local anesthetic systemic toxicity is a&#xD;
      potential complication of regional anesthesia as well. For this reason, dilute anesthetic is&#xD;
      used, and a maximum dose of 2 mg/kg of bupivacaine is the recommendation. Pneumothorax is a&#xD;
      potential complication but would entail catastrophic error because the fascial planes&#xD;
      targeted in this block are superficial to the ribs, and the pleural line can be visualized&#xD;
      clearly on ultrasound. If a pneumothorax is suspected, ultrasound can help to confirm lung&#xD;
      sliding immediately after the procedure. Nerve injury is unlikely given the needle is not&#xD;
      steered directly at nerves, but instead towards the plane through which the nerves run.&#xD;
&#xD;
      The duration of traditional amide-based and ester-based regional anesthesia is normally&#xD;
      limited to only a few hours as mentioned above. Techniques including continuous catheter&#xD;
      placement or serial injections can be used to enhance the duration and effect of regional&#xD;
      anesthesia for postoperative pain control. But these approaches can increase the risk of&#xD;
      infection, toxicity, and cost. Therefore, alternative methods of extending the clinical&#xD;
      duration of nerve blocks have been a topic of significant interest.&#xD;
&#xD;
      At SJMO patients who undergo a thoracoscopic procedures currently receive parenteral opioids&#xD;
      or thoracic epidurals for management of pain.&#xD;
&#xD;
      The purpose of this study is to determine whether SAPB with bupivacaine and adjuvants can&#xD;
      provide superior pain management (decrease pain scores) and decrease opioid consumption,&#xD;
      without increasing nausea/vomiting, compared to patients receiving SAPB with bupivacaine&#xD;
      alone in patients undergoing video-assisted thoracoscopy.&#xD;
&#xD;
      We will be assessing whether the addition of magnesium and buprenorphine to bupivacaine in&#xD;
      SAPB will decrease visual analog scale (VAS) pain scores, reduce post-operative total opioid&#xD;
      consumption (oral morphine equivalents), and decrease post-operative nausea and vomiting&#xD;
      (PONV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative total opioid consumption (oral morphine equivalents)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Total Opioid consumption 24 hours post surgery oral moral morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analog scale (VAS) pain scores</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>Pain Scores measured via a Visual Analog Scale (0-10, Higher scores mean worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analog scale (VAS) pain scores</measure>
    <time_frame>12 hours after surgery</time_frame>
    <description>Pain Scores measured via a Visual Analog Scale (0-10, Higher scores mean worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analog scale (VAS) pain scores</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Pain Scores measured via a Visual Analog Scale (0-10, Higher scores mean worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operation nausea and vomiting (PONV)</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of the patients who had post-operative nausea and vomiting (PONV) within 24 hours of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen consumption</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Total acetaminophen consumption in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSAID (ketorolac) consumption</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Total NSAID consumption in mg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Post Operative Pain, Acute</condition>
  <arm_group>
    <arm_group_label>SAPB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 Patients - Patients will receive 30 mL of 0.25% bupivacaine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAPB with Mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAPB with Mg and Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg and 300 mcg of buprenorphine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.25% Injectable Solution</intervention_name>
    <description>Injection of Bupivacaine 0.25% Injectable Solution for SAPB</description>
    <arm_group_label>SAPB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg</intervention_name>
    <description>Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant</description>
    <arm_group_label>SAPB with Mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg</intervention_name>
    <description>Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants</description>
    <arm_group_label>SAPB with Mg and Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients undergoing video-assisted thoracoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significant genetic or acquired clotting/bleeding disorders (hemophilia,&#xD;
             DIC, etc.)&#xD;
&#xD;
          -  Patients with significant platelet dysfunction&#xD;
&#xD;
          -  Infection at site for regional anesthesia&#xD;
&#xD;
          -  Allergy to local anesthetics&#xD;
&#xD;
          -  Sepsis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandeep Krishnan, M.D.</last_name>
    <phone>(248) 858-6068</phone>
    <email>sakrishna@med.wayne.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph Mercy Oakland Hospital</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Anderson</last_name>
      <phone>248-858-6068</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Sandeep Krishnan</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Serratus anterior plane block, video-assisted thoracoscopy, opioid consumption, magnesium, buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

